NO20003211D0 - Triazinforbindelser for behandling av CNS forstyrrelser - Google Patents

Triazinforbindelser for behandling av CNS forstyrrelser

Info

Publication number
NO20003211D0
NO20003211D0 NO20003211A NO20003211A NO20003211D0 NO 20003211 D0 NO20003211 D0 NO 20003211D0 NO 20003211 A NO20003211 A NO 20003211A NO 20003211 A NO20003211 A NO 20003211A NO 20003211 D0 NO20003211 D0 NO 20003211D0
Authority
NO
Norway
Prior art keywords
treatment
cns disorders
triazine compounds
triazine
cns
Prior art date
Application number
NO20003211A
Other languages
English (en)
Other versions
NO20003211L (no
Inventor
Brian Cox
Mark Patrick Healy
Malcolm Stuart Nobbs
Gita Punjabhai Shah
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20003211D0 publication Critical patent/NO20003211D0/no
Publication of NO20003211L publication Critical patent/NO20003211L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20003211A 1997-12-22 2000-06-21 Triazinforbindelser for behandling av CNS forstyrrelser NO20003211L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726987.2A GB9726987D0 (en) 1997-12-22 1997-12-22 Compounds
PCT/EP1998/008273 WO1999032462A1 (en) 1997-12-22 1998-12-18 Triazine compounds for treatment of cns disorders

Publications (2)

Publication Number Publication Date
NO20003211D0 true NO20003211D0 (no) 2000-06-21
NO20003211L NO20003211L (no) 2000-08-21

Family

ID=10823992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003211A NO20003211L (no) 1997-12-22 2000-06-21 Triazinforbindelser for behandling av CNS forstyrrelser

Country Status (34)

Country Link
US (2) US6265405B1 (no)
EP (1) EP1042304A1 (no)
JP (1) JP2001526275A (no)
KR (1) KR20010024800A (no)
CN (1) CN1284951A (no)
AP (1) AP2000001846A0 (no)
AR (1) AR014146A1 (no)
AU (1) AU753874B2 (no)
BR (1) BR9814495A (no)
CA (1) CA2315620A1 (no)
CO (1) CO5011066A1 (no)
EA (1) EA200000561A1 (no)
EE (1) EE200000391A (no)
GB (1) GB9726987D0 (no)
GT (1) GT199800203A (no)
HN (1) HN1998000193A (no)
HR (1) HRP20000419A2 (no)
HU (1) HUP0100611A3 (no)
ID (1) ID25449A (no)
IL (1) IL136867A0 (no)
IS (1) IS5542A (no)
JO (1) JO2065B1 (no)
MA (1) MA26587A1 (no)
NO (1) NO20003211L (no)
NZ (1) NZ505254A (no)
PA (1) PA8465101A1 (no)
PE (1) PE20000063A1 (no)
PL (1) PL341392A1 (no)
SK (1) SK9592000A3 (no)
SV (1) SV1998000151A (no)
TR (1) TR200001970T2 (no)
WO (1) WO1999032462A1 (no)
YU (1) YU39600A (no)
ZA (1) ZA9811725B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
ES2286328T3 (es) * 2001-12-27 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Aroilpirrolheteroaril y metanoles utiles para tratar transtornos del sistema nervioso central.
CN100363007C (zh) * 2002-07-29 2008-01-23 葛兰素集团有限公司 含拉莫三嗪的缓释制剂
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ, インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10332472A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Tinnitus
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
TWI704139B (zh) 2015-08-17 2020-09-11 日商日本煙草產業股份有限公司 羥基三化合物及其醫藥用途
EP3524605B1 (en) * 2018-02-13 2019-11-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. New efficient process for the preparation of sitagliptin
CN114796146B (zh) * 2022-04-28 2023-03-28 上海奥科达医药科技股份有限公司 一种拉莫三嗪的缓释制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
JPS5625170A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
EP0021121B1 (en) * 1979-06-01 1983-05-11 The Wellcome Foundation Limited 1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
IT1145308B (it) 1979-08-16 1986-11-05 Wellcome Found Composti aromatici sostituiti
GB8328757D0 (en) 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9203483D0 (en) 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
AU688729B2 (en) 1992-06-12 1998-03-19 Wellcome Foundation Limited, The Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate for the treatment and prevention of dependence, tolerance and sensitization of drugs
JPH08504798A (ja) 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての,ピリミジン,ピリジン,プテリジノンおよびインダゾール誘導体
US5866597A (en) 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305692D0 (en) 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
FR2741879A1 (fr) 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament

Also Published As

Publication number Publication date
NO20003211L (no) 2000-08-21
HUP0100611A2 (hu) 2001-09-28
US6265405B1 (en) 2001-07-24
AU2414799A (en) 1999-07-12
ZA9811725B (en) 2000-06-27
GT199800203A (es) 2000-06-14
IS5542A (is) 2000-06-20
SK9592000A3 (en) 2001-03-12
WO1999032462A1 (en) 1999-07-01
AR014146A1 (es) 2001-02-07
AP2000001846A0 (en) 2000-06-30
IL136867A0 (en) 2001-06-14
NZ505254A (en) 2002-06-28
GB9726987D0 (en) 1998-02-18
HN1998000193A (es) 2000-04-05
ID25449A (id) 2000-10-05
EA200000561A1 (ru) 2001-04-23
EE200000391A (et) 2002-02-15
SV1998000151A (es) 1999-07-05
EP1042304A1 (en) 2000-10-11
CA2315620A1 (en) 1999-07-01
HRP20000419A2 (en) 2000-12-31
PA8465101A1 (es) 2000-09-29
AU753874B2 (en) 2002-10-31
TR200001970T2 (tr) 2001-01-22
CO5011066A1 (es) 2001-02-28
PE20000063A1 (es) 2000-02-16
US6465461B1 (en) 2002-10-15
MA26587A1 (fr) 2004-12-20
JO2065B1 (en) 2000-05-21
HUP0100611A3 (en) 2003-03-28
JP2001526275A (ja) 2001-12-18
CN1284951A (zh) 2001-02-21
YU39600A (sh) 2002-11-15
KR20010024800A (ko) 2001-03-26
BR9814495A (pt) 2000-10-10
PL341392A1 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
NO972869L (no) Fremgangsmåte for fremstilling av höyrent melamin
NO972909D0 (no) Substituerte azetidin-2-oner for behandling av atherosklerose
DK0769947T3 (da) Indolinonforbindelser til behandling af sygdom
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO306977B1 (no) Anvendelse av tienol[1,5]benzodiazepin for behandling av tilstander i mave/tarmkanalen
FI962249A7 (fi) Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
NO20011892D0 (no) 3-tetrahydropyridin-4-yl-indoler for behandling av psykotiske forstyrrelser
NO20026005L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
ID21920A (id) 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns
NO20030127D0 (no) Indolderivater nyttige for behandling av CNS-forstyrrelser
DK1458703T3 (da) Isochromanforbindelser til behandling af CNS-lidelser
NO20026029D0 (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO993549L (no) Imino-aza-antracyklinonderivater til behandling av amyloidosis
NO993948D0 (no) Anvendelse av aryl-cykloheksylamin-derivater mot CNS-forstyrrelser
NO20026028L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO20005351D0 (no) Paroksetin 10-kamfersulfonat for behandling av CNS lidelser
HK1028609A (en) Triazine compounds for treatment of cns disorders
NO962812D0 (no) Fremgangsmåte for behandling av nervebetennelse
IL122077A0 (en) Epi-inositol compositions for the treatment of CNS disorders
NO996166D0 (no) Fremgangsmåte for behandling av avluter